PRESS RELEASE

Q1 2022 — Press release

Q1 2022PDF · 19 pages420 KB
FOR IMMEDIATE RELEASE
• Total sales growth of 5.0% to $23.4 Billion with operational growth of 7.7%* and adjusted operational
growth of 7.9%*
• Earnings per share of $1.93 decreasing 16.8% and adjusted earnings per share of $2.67 increasing 3.1%*
• Company maintaining 2022 full-year guidance for adjusted operational earnings per share and base
business operational sales
• Given global supply surplus and demand uncertainty, the Company is suspending COVID-19 Vaccine sales
guidance, with no impact to adjusted operational earnings per share guidance
New Brunswick, N.J. (April 19, 2022) – Johnson & Johnson (NYSE: JNJ) today announced results for first-quarter
2022. “Our first quarter results demonstrate strong performance across the enterprise, despite macro-economic
headwinds. I am incredibly proud of Johnson & Johnson’s 144,000 employees for their relentless passion and Credo-
based commitment to delivering transformative healthcare solutions to patients and customers around the world,” said
Joaquin Duato, Chief Executive Officer. “Looking ahead, I remain confident in the future of Johnson & Johnson as we
continue advancing our portfolio and innovative pipeline.”
OVERALL FINANCIAL RESULTS
1 Non-GAAP financial measure; refer to reconciliations of non-GAAP financial measures included in accompanying schedules
2 Excludes the impact of translational currency
3 Excludes the net impact of acquisitions and divestitures and translational currency
4 Excludes intangible amortization expense and special items
Note: values may have been rounded
($ in Millions, except EPS) 2022 2021 % Change
Reported Sales 23,426	$ 22,321	$ 5.0%
Net Earnings 5,149 6,197 (16.9)%
EPS (diluted) 1.93	$ 2.32	$ (16.8)%
Non-GAAP* ($ in Millions, except EPS) 2022 2021 % Change
Operational Sales1,2 7.7%
Adjusted Operational Sales1,3 7.9%
Adjusted Net Earnings1,4 7,129 6,924 3.0%
Adjusted EPS (diluted)1,4 2.67	$ 2.59	$ 3.1%
Q1
Q1

-- 1 of 19 --

REGIONAL SALES RESULTS
1 Non-GAAP financial measure; refer to reconciliations of non-GAAP financial measures included in accompanying schedules
2 Excludes the impact of translational currency
3 Excludes the net impact of acquisitions and divestitures and translational currency
Note: values may have been rounded
SEGMENT SALES RESULTS
1 Non-GAAP financial measure; refer to reconciliations of non-GAAP financial measures included in accompanying schedules
2 Excludes the impact of translational currency
3 Excludes the net impact of acquisitions and divestitures and translational currency
4 Certain international OTC products, primarily in China, were reclassified from the Pharmaceutical segment to the Consumer Health segment based on
operational changes in their respective regions
Note: The MedTech segment was previously referred to as the Medical Devices segment
Values may have been rounded
Q1
($ in Millions) 2022 2021 Reported Operational1,2 Currency
Adjusted
Operational1,3
Consumer Health4 3,586	$ 3,641	$ (1.5)% 0.8 (2.3) 1.6
Pharmaceutical4 12,869 12,101 6.3% 9.3 (3.0) 9.3
MedTech 6,971 6,579 5.9% 8.5 (2.6) 8.6
Worldwide 23,426	$ 22,321	$ 5.0% 7.7 (2.7) 7.9
% Change

-- 2 of 19 --

FIRST QUARTER 2022 SEGMENT COMMENTARY:
Consumer Health
Consumer Health worldwide adjusted operational sales, which exclude the net impact of acquisitions and
divestitures and translational currency, increased 1.6%* primarily driven by over-the-counter (OTC) products.
Major contributors to growth in OTC were upper respiratory products, TYLENOL and MOTRIN analgesics, and
IMODIUM in digestive health products. Growth was partially offset by external supply constraints mainly
impacting Skin Health / Beauty.
Pharmaceutical
Pharmaceutical worldwide adjusted operational sales, which exclude the net impact of acquisitions and
divestitures and translational currency, grew 9.3%* driven by DARZALEX (daratumumab), a biologic for the
treatment of multiple myeloma, STELARA (ustekinumab), a biologic for the treatment of a number of immune-
mediated inflammatory diseases, TREMFYA (guselkumab), a biologic for the treatment of adults living with
moderate to severe plaque psoriasis, and for adults with active psoriatic arthritis, ERLEADA (apalutamide), a
next-generation androgen receptor inhibitor for the treatment of patients with prostate cancer, and INVEGA
SUSTENNA/XEPLION and INVEGA TRINZA/TREVICTA (paliperidone palmitate), long-acting, injectable
atypical antipsychotics for the treatment of schizophrenia in adults. Also contributing to growth were sales of the
Janssen COVID-19 Vaccine (Ad26.COV2.S) for the prevention of the SARS-CoV-2 virus. This growth was
partially offset by declines in sales of REMICADE (infliximab), a biologic approved for the treatment of a number
of immune-mediated inflammatory diseases, XARELTO (rivaroxaban), a direct oral anticoagulant, and ZYTIGA
(abiratone acetate), an oral, once-daily medication for use in combination with prednisone for the treatment of
metastatic castration-resistant prostate cancer.
MedTech
MedTech worldwide adjusted operational sales, which exclude the net impact of acquisitions and divestitures
and translational currency, grew 8.6%*, driven by electrophysiology products in Interventional Solutions, contact
lenses and surgical vision products in Vision, wound closure products in General Surgery, biosurgery in
Advanced Surgery, and hips, trauma, and knees in Orthopaedics.

-- 3 of 19 --

NOTABLE NEW ANNOUCEMENTS IN THE QUARTER:
The information contained in this section should be read in conjunction with Johnson & Johnson’s other
disclosures filed with the Securities and Exchange Commission, including its Current Reports on Form 8-K,
Quarterly Reports on Form 10-Q and Annual Reports on Form 10-K. Copies of these filings are available online
at www.sec.gov, www.jnj.com or on request from Johnson & Johnson. The reader is also encouraged to review
all other news releases and information available in the Investors section of the company’s website
at news releases, as well as www.factsabouttalc.com, www.factsaboutourprescriptionopioids.com, and
www.LTLManagementInformation.com.
Regulatory
Decisions
U.S. FDA Approves CARVYKTI (ciltacabtagene autoleucel), Janssen’s First Cell
Therapy, a BCMA-Directed CAR-T Immunotherapy for the Treatment of Patients
with Relapsed or Refractory Multiple Myeloma
(press release)
U.S. FDA Approves CABENUVA (rilpivirine and cabotegravir) for Use Every Two
Months, Expanding the Label of the First and Only Long-Acting HIV Treatment (press release)
U.S. FDA Approves CABENUVA (cabotegravir and rilpivirine) for Adolescents,
Expanding the Indication of the First and Only Complete Long-Acting Injectable HIV
Regimen1
(press release)
U.S. FDA Approves Streamlined Process for Initiating HIV Therapy with
CABENUVA (cabotegravir and rilpivirine), the First and Only Complete Long-Acting
Injectable HIV Treatment
(press release)
Regulatory
Submissions
Janssen Submits Marketing Authorisation Application to the European Medicines
Agency Seeking Approval of Bispecific Antibody Teclistamab for the Treatment of
Patients with Relapsed or Refractory Multiple Myeloma
(press release)
Janssen Seeks Approval of a New Indication for IMBRUVICA (ibrutinib) for Use in
Patients with Untreated Mantle Cell Lymphoma (press release)
Other
Janssen Presents New Data Demonstrating the Combination of Niraparib and
Abiraterone Acetate Plus Prednisone Significantly Improved Radiographic
Progression-Free Survival as a First-Line Therapy in Patients with HRR Gene-
Mutated Metastatic Castration-Resistant Prostate Cancer
(press release)
Johnson & Johnson Statement on Nationwide Opioid Settlement Agreement (press release)
DePuy Synthes Further Reimagines Knee Restoration with the Addition of Two
New Innovations to the ATTUNE Knee Portfolio (press release)
Janssen Initiates First-of-its-Kind Clinical Study to Bridge Critical Gaps in Care for
People of Color with Moderate to Severe Plaque Psoriasis (press release)
Johnson & Johnson Statement on War in Ukraine (press release)
1Subsequent to the quarter

-- 4 of 19 --

FULL-YEAR 2022 GUIDANCE:
Johnson & Johnson does not provide GAAP financial measures on a forward-looking basis because the company
is unable to predict with reasonable certainty the ultimate outcome of legal proceedings, unusual gains and
losses, acquisition-related expenses and purchase accounting fair value adjustments without unreasonable
effort. These items are uncertain, depend on various factors, and could be material to Johnson & Johnson's
results computed in accordance with GAAP.
Please note that the Company has suspended guidance on its COVID-19 Vaccine sales. The table below
excludes COVID-19 Vaccine sales from Adjusted Operational Sales, Operational Sales, and Estimated Reported
Sales.
($ in Billions, except EPS) April 2022 January 2022
Adjusted Operational Sales1,2,5
Change vs. Prior Year 6.5% – 7.5% 6.5% – 7.5%
Operational Sales2,5
Change vs. Prior Year
$97.3B – $98.3B
6.5% – 7.5%
$97.3B – $98.3B
6.5% – 7.5%
Estimated Reported Sales3,5
Change vs. Prior Year
$94.8B – $95.8B
3.8% – 4.8%
$95.9B - $96.9B
5.0% – 6.0%
Adjusted Operational EPS (Diluted)2,4
Change vs. Prior Year
$10.60 - $10.80
8.2% – 10.2%
$10.60 - $10.80
8.2% – 10.2%
Adjusted EPS (Diluted)3,4
Change vs. Prior Year
$10.15 - $10.35
3.6% – 5.6%
$10.40 - $10.60
6.1% – 8.2%
1 Non-GAAP financial measure; excludes the net impact of acquisitions and divestitures
2 Non-GAAP financial measure; excludes the impact of translational currency
3 Calculated using Euro Average Rate: January 2022 = $1.14 and April = $1.09 (Illustrative purposes only)
4 Non-GAAP financial measure; excludes intangible amortization expense and special items
5 Excludes COVID-19 Vaccine
Note: percentages may have been rounded
Other modeling considerations will be provided on the webcast.

-- 5 of 19 --

WEBCAST INFORMATION:
Johnson & Johnson will conduct a conference call with investors to discuss this earnings release today at 8:30
a.m., Eastern Time. A simultaneous webcast of the call for investors and other interested parties may be
accessed by visiting the Johnson & Johnson website. A replay and podcast will be available approximately two
hours after the live webcast in the Investors section of the company's website at events-and-presentations.
ABOUT JOHNSON & JOHNSON:
At Johnson & Johnson, we believe good health is the foundation of vibrant lives, thriving communities and forward
progress. That’s why for more than 130 years, we have aimed to keep people well at every age and every stage
of life. Today, as the world’s largest and most broadly-based health care company, we are committed to using
our reach and size for good. We strive to improve access and affordability, create healthier communities, and put
a healthy mind, body and environment within reach of everyone, everywhere. We are blending our heart, science
and ingenuity to profoundly change the trajectory of health for humanity.
NON-GAAP FINANCIAL MEASURES:
* “Operational sales growth” excluding the impact of translational currency, “adjusted operational sales growth”
excluding the net impact of acquisitions and divestitures and translational currency, as well as “adjusted net
earnings”, “adjusted diluted earnings per share” and “adjusted operational diluted earnings per share” excluding
after-tax intangible amortization expense and special items, are non-GAAP financial measures and should not
be considered replacements for, and should be read together with, the most comparable GAAP financial
measures. Except for guidance measures, reconciliations of these non-GAAP financial measures to the most
directly comparable GAAP financial measures can be found in the accompanying financial schedules of the
earnings release and the Investors section of the company's website at quarterly-results.
Copies of the financial schedules accompanying this earnings release are available on the company’s website
at quarterly-results. These schedules include supplementary sales data, a condensed consolidated statement of
earnings, reconciliations of non-GAAP financial measures, and sales of key products/franchises. Additional
information on Johnson & Johnson, including adjusted income before tax by segment, a pharmaceutical pipeline
of selected compounds in late stage development and a copy of today’s earnings call presentation can also be
found in the Investors section of the company's website at quarterly-results.

-- 6 of 19 --

NOTE TO INVESTORS CONCERNING FORWARD-LOOKING STATEMENTS:
This press release contains “forward-looking statements” as defined in the Private Securities Litigation Reform Act
of 1995 regarding, among other things: future operating and financial performance, product development, market
position and business strategy, and the anticipated separation of the Company’s Consumer Health business. The
reader is cautioned not to rely on these forward-looking statements. These statements are based on current
expectations of future events. If underlying assumptions prove inaccurate or known or unknown risks or
uncertainties materialize, actual results could vary materially from the expectations and projections of Johnson &
Johnson. Risks and uncertainties include, but are not limited to: economic factors, such as interest rate and
currency exchange rate fluctuations; competition, including technological advances, new products and patents
attained by competitors; challenges inherent in new product research and development, including uncertainty of
clinical success and obtaining regulatory approvals; uncertainty of commercial success for new and existing
products; challenges to patents; the impact of patent expirations; the ability of the company to successfully
execute strategic plans; the impact of business combinations and divestitures; manufacturing difficulties or delays,
internally or within the supply chain; product efficacy or safety concerns resulting in product recalls or regulatory
action; significant adverse litigation or government action, including related to product liability claims; changes to
applicable laws and regulations, including tax laws and global health care reforms; trends toward health care cost
containment; changes in behavior and spending patterns of purchasers of health care products and services;
financial instability of international economies and legal systems and sovereign risk; increased scrutiny of the
health care industry by government agencies; the Company’s ability to satisfy the necessary conditions to
consummate the separation of the Company’s Consumer Health business on a timely basis or at all; the
Company’s ability to successfully separate the Company’s Consumer Health business and realize the anticipated
benefits from the separation; the New Consumer Health Company’s ability to succeed as a standalone publicly
traded company; and risks related to the impact of the COVID-19 global pandemic, such as the scope and
duration of the outbreak, government actions and restrictive measures implemented in response, material delays
and cancellations of medical procedures, supply chain disruptions and other impacts to the business, or on the
company’s ability to execute business continuity plans, as a result of the COVID-19 pandemic. A further list and
descriptions of these risks, uncertainties and other factors can be found in Johnson & Johnson’s Annual Report
on Form 10-K for the fiscal year ended January 2, 2022, including in the sections captioned “Cautionary Note
Regarding Forward-Looking Statements” and “Item 1A. Risk Factors,” and in Johnson & Johnson’s subsequent
Quarterly Reports on Form 10-Q and other filings with the Securities and Exchange Commission. Copies of these
filings are available online at www.sec.gov, www.jnj.com or on request from Johnson & Johnson. Any forward-
looking statement made in this release speaks only as of the date of this release. Johnson & Johnson does not
undertake to update any forward-looking statement as a result of new information or future events or
developments.
Press Contacts: Investor Contacts:
Lindsay Hymson Jessica Moore Lisa Romanko
(516) 524 1757 (732) 524-2955 (732) 524-2034

-- 7 of 19 --

Johnson & Johnson and Subsidiaries
Supplementary Sales Data
(Unaudited; Dollars in Millions)
2022 2021 Total Operations Currency
Sales to customers by
segment of business
Consumer Health (1)
U.S. 1,557	$ 1,611 (3.4) % (3.4) -
International 2,029 2,030 0.0 4.1 (4.1)
3,586 3,641 (1.5) 0.8 (2.3)
Pharmaceutical (1)
U.S. 6,632 6,446 2.9 2.9 -
International 6,237 5,655 10.3 16.7 (6.4)
12,869 12,101 6.3 9.3 (3.0)
MedTech (2)
U.S. 3,225 3,054 5.6 5.6 -
International 3,746 3,525 6.3 11.1 (4.8)
6,971 6,579 5.9 8.5 (2.6)
U.S. 11,414 11,111 2.7 2.7 -
International 12,012 11,210 7.2 12.6 (5.4)
Worldwide 23,426	$ 22,321 5.0 % 7.7 (2.7)
Note: Percentages have been calculated using actual, non-rounded figures and, therefore, may not recalculate precisely.
FIRST QUARTER
Percent Change
(1) Certain international OTC products, primarily in China, were reclassified from the Pharmaceutical segment to the Consumer Health segment based on operational
changes in their respective regions
(2) Previously referred to as Medical Devices

-- 8 of 19 --

Johnson & Johnson and Subsidiaries
Supplementary Sales Data
(Unaudited; Dollars in Millions)
2022 2021 Total Operations Currency
Sales to customers by
geographic area
U.S. 11,414	$ 11,111 2.7 % 2.7 -
Europe 6,024 5,414 11.3 19.5 (8.2)
Western Hemisphere excluding U.S. 1,482 1,424 4.1 5.1 (1.0)
Asia-Pacific, Africa 4,506 4,372 3.1 6.6 (3.5)
International 12,012 11,210 7.2 12.6 (5.4)
Worldwide 23,426	$ 22,321 5.0 % 7.7 (2.7)
Note: Percentages have been calculated using actual, non-rounded figures and, therefore, may not recalculate precisely.
FIRST QUARTER
Percent Change

-- 9 of 19 --

Johnson & Johnson and Subsidiaries
Condensed Consolidated Statement of Earnings
(Unaudited; in Millions Except Per Share Figures)
Percent
Percent Percent Increase
Amount to Sales Amount to Sales (Decrease)
Sales to customers 23,426	$ 100.0 22,321	$ 100.0 5.0
Cost of products sold 7,598 32.4 7,063 31.7 7.6
Gross Profit 15,828 67.6 15,258 68.3 3.7
Selling, marketing and administrative expenses 5,938 25.4 5,432 24.3 9.3
Research and development expense 3,462 14.8 3,178 14.2 8.9
In-process research and development 610 2.6 - -
Interest (income) expense, net (12) (0.1) 48 0.2
Other (income) expense, net (102) (0.4) (882) (3.9)
Restructuring 70 0.3 53 0.2
Earnings before provision for taxes on income 5,862 25.0 7,429 33.3 (21.1)
Provision for taxes on income 713 3.0 1,232 5.5 (42.1)
Net earnings 5,149 22.0 6,197 27.8 (16.9)
Net earnings per share (Diluted) 1.93	$ 2.32	$ (16.8)
Average shares outstanding (Diluted) 2,666.5 2,672.7
Effective tax rate 12.2 % 16.6 %
Adjusted earnings before provision for taxes and net earnings (1)
Earnings before provision for taxes on income 8,218	$ 35.1 8,291	$ 37.1 (0.9)
Net earnings 7,129	$ 30.4 6,924	$ 31.0 3.0
Net earnings per share (Diluted) 2.67	$ 2.59	$ 3.1
Effective tax rate 13.3 % 16.5 %
(1) See Reconciliation of Non-GAAP Financial Measures.
FIRST QUARTER
2022 2021

-- 10 of 19 --

Johnson & Johnson and Subsidiaries
Reconciliation of Non-GAAP Financial Measures
(Dollars in Millions Except Per Share Data) 2022 2021
Net Earnings, after tax- as reported $5,149 $6,197
Pre-tax Adjustments
Intangible Asset Amortization expense 1,108 1,215
IPR&D 610 -
Restructuring related 72 104
Acquisition, integration and divestiture related ¹ - (538)
(Gains)/losses on securities 411 35
Medical Device Regulation 2 60 46
Consumer Health separation costs 102 -
Other (7) -
Tax Adjustments
Tax impact on special item adjustments 3 (393) (113)
Consumer Health separation tax related costs 96 -
Tax legislation and other tax related (79) (22)
Adjusted Net Earnings, after tax $7,129 $6,924
Average shares outstanding (Diluted) 2,666.5 2,672.7
Adjusted net earnings per share (Diluted) $2.67 $2.59
Operational adjusted net earnings per share (Diluted) $2.75
Notes:
1
2
3
First Quarter
Acquisition, integration and divestiture related for the first quarter of 2021 primarily includes the gain on the divestiture of 2
Pharmaceutical brands outside of the U.S.
The tax impact related to special item adjustments reflects the current and deferred income taxes associated with the above pre-
tax special items in arriving at adjusted earnings.
European Medical Device Regulation (MDR) costs represent one-time compliance costs for the Company’s previously registered
products. MDR is a replacement of the existing European Medical Devices Directive regulatory framework, and manufacturers of
currently marketed medical devices were required to comply with EU MDR beginning in May 2021. The Company considers the
adoption of EU MDR to be a significant one-time regulatory change and is not indicative of on-going operations. The Company
has excluded only external third-party regulatory and consulting costs from its MedTech operating segments' measures of profit
and loss used for making operating decisions and assessing performance which is expected to be completed by the end of 2023.

-- 11 of 19 --

Johnson & Johnson and Subsidiaries
Reconciliation of Non-GAAP Financial Measure
Consumer Health Pharmaceutical MedTech Total
WW As Reported (1.5)% 6.3% 5.9% 5.0%
U.S. (3.4)% 2.9% 5.6% 2.7%
International 0.0% 10.3% 6.3% 7.2%
WW Currency (2.3) (3.0) (2.6) (2.7)
U.S. - - - -
International (4.1) (6.4) (4.8) (5.4)
WW Operational 0.8% 9.3% 8.5% 7.7%
U.S. (3.4)% 2.9% 5.6% 2.7%
International 4.1% 16.7% 11.1% 12.6%
Skin Health / Beauty
Dr. Ci Labo - Sedona 0.6 0.1
U.S. 0.0 0.0
International 1.1 0.2
All Other Acquisitions and Divestitures 0.2 0.0 0.1 0.1
U.S. 0.2 0.0 0.1 0.1
International 0.1 0.0 0.1 0.1
WW Adjusted Operational 1.6% 9.3% 8.6% 7.9%
U.S. (3.2)% 2.9% 5.7% 2.8%
International 5.3% 16.7% 11.2% 12.9%
Adjusted Operational Sales Growth
FIRST QUARTER 2022 ACTUAL vs. 2021 ACTUAL
Segments
Note: Percentages are based on actual, non-rounded figures and may not sum.

-- 12 of 19 --

REPORTED SALES vs. PRIOR PERIOD ($MM)
FIRST QUARTER
2022 2021 Reported Operational (1) Currency
CONSUMER HEALTH SEGMENT (2,3)
OTC (5)
US 670	$ 599 11.8% 11.8% -
Intl 791 673 17.5% 21.7% -4.2%
WW 1,461 1,273 14.8% 17.1% -2.3%
SKIN HEALTH / BEAUTY
US 544 634 -14.2% -14.2% -
Intl 468 529 -11.6% -7.1% -4.5%
WW 1,012 1,163 -13.0% -11.0% -2.0%
ORAL CARE
US 143 163 -12.6% -12.6% -
Intl 223 254 -12.0% -8.6% -3.4%
WW 366 417 -12.2% -10.2% -2.0%
BABY CARE
US 85 96 -11.5% -11.5% -
Intl 270 293 -7.7% -4.8% -2.9%
WW 355 389 -8.6% -6.4% -2.2%
WOMEN'S HEALTH
US 3 3 7.2% 7.2% -
Intl 224 219 2.5% 8.3% -5.8%
WW 228 222 2.6% 8.3% -5.7%
WOUND CARE / OTHER
US 112 115 -3.3% -3.3% -
Intl 52 61 -15.3% -14.5% -0.8%
WW 164 177 -7.4% -7.2% -0.2%
TOTAL CONSUMER HEALTH
US 1,557 1,611 -3.4% -3.4% -
Intl 2,029 2,030 0.0% 4.1% -4.1%
WW 3,586	$ 3,641 -1.5% 0.8% -2.3%
See footnotes at end of schedule
% Change

-- 13 of 19 --

REPORTED SALES vs. PRIOR PERIOD ($MM)
FIRST QUARTER
PHARMACEUTICAL SEGMENT (2,3) 2022 2021 Reported Operational (1) Currency
IMMUNOLOGY
US 2,501	$ 2,413 3.7% 3.7% -
Intl 1,617 1,501 7.7% 13.7% -6.0%
WW 4,119 3,914 5.2% 7.5% -2.3%
REMICADE
US 358 489 -26.8% -26.8% -
US Exports (4) 80 57 40.5% 40.5% -
Intl 225 232 -2.6% -1.0% -1.6%
WW 663 777 -14.7% -14.2% -0.5%
SIMPONI / SIMPONI ARIA
US 287 255 12.5% 12.5% -
Intl 283 307 -7.6% -1.9% -5.7%
WW 571 562 1.5% 4.7% -3.2%
STELARA
US 1,379 1,331 3.6% 3.6% -
Intl 909 817 11.2% 17.8% -6.6%
WW 2,288 2,148 6.5% 9.0% -2.5%
TREMFYA
US 391 274 42.7% 42.7% -
Intl 199 143 38.8% 47.9% -9.1%
WW 590 418 41.3% 44.5% -3.2%
OTHER IMMUNOLOGY
US 6 7 -3.2% -3.2% -
Intl 0 2 * * *
WW 6 8 -22.0% -22.0% -
INFECTIOUS DISEASES (5)
US 461 512 -10.0% -10.0% -
Intl 836 485 72.3% 78.6% -6.3%
WW 1,297 998 30.0% 33.1% -3.1%
COVID-19 VACCINE
US 75 100 -24.9% -24.9% -
Intl 382 0 * * *
WW 457 100 * * *
EDURANT / rilpivirine
US 9 10 -12.6% -12.6% -
Intl 239 233 2.5% 10.5% -8.0%
WW 248 243 1.8% 9.6% -7.8%
PREZISTA / PREZCOBIX / REZOLSTA / SYMTUZA
US 369 380 -3.1% -3.1% -
Intl 132 166 -20.3% -15.9% -4.4%
WW 501 546 -8.3% -6.9% -1.4%
OTHER INFECTIOUS DISEASES
US 8 21 -62.5% -62.5% -
Intl 83 87 -3.8% 1.6% -5.4%
WW 91 108 -15.3% -11.0% -4.3%
% Change

-- 14 of 19 --

REPORTED SALES vs. PRIOR PERIOD ($MM)
FIRST QUARTER
2022 2021 Reported Operational (1) Currency
NEUROSCIENCE (5)
US 843 771 9.3% 9.3% -
Intl 898 943 -4.8% 1.5% -6.3%
WW 1,741 1,715 1.5% 5.0% -3.5%
CONCERTA / Methylphenidate
US 35 47 -26.5% -26.5% -
Intl 122 123 -1.3% 3.5% -4.8%
WW 157 171 -8.3% -4.8% -3.5%	INVEGA SUSTENNA / XEPLION /
INVEGA TRINZA / TREVICTA
US 661 589 12.2% 12.2% -
Intl 387 376 3.0% 9.9% -6.9%
WW 1,048 965 8.6% 11.3% -2.7%
RISPERDAL CONSTA
US 63 67 -6.4% -6.4% -
Intl 66 89 -26.1% -19.6% -6.5%
WW 129 157 -17.6% -13.9% -3.7%
OTHER NEUROSCIENCE
US 84 67 25.5% 25.5% -
Intl 323 355 -8.9% -2.8% -6.1%
WW 408 422 -3.5% 1.7% -5.2%
ONCOLOGY
US 1,582 1,377 14.9% 14.9% -
Intl 2,369 2,193 8.0% 15.0% -7.0%
WW 3,950 3,570 10.6% 14.9% -4.3%
DARZALEX
US 953 691 37.9% 37.9% -
Intl 903 674 34.0% 42.7% -8.7%
WW 1,856 1,365 36.0% 40.3% -4.3%
ERLEADA
US 206 171 20.3% 20.3% -
Intl 194 90 * * *
WW 400 261 53.0% 57.5% -4.5%
IMBRUVICA
US 370 444 -16.7% -16.7% -
Intl 668 680 -1.8% 4.5% -6.3%
WW 1,038 1,125 -7.7% -3.9% -3.8%
ZYTIGA / abiraterone acetate
US 19 50 -62.1% -62.1% -
Intl 520 588 -11.6% -5.7% -5.9%
WW 539 638 -15.6% -10.1% -5.5%
OTHER ONCOLOGY
US 34 21 63.1% 63.1% -
Intl 84 161 -47.7% -44.6% -3.1%
WW 118 182 -35.1% -32.3% -2.8%
% Change

-- 15 of 19 --

REPORTED SALES vs. PRIOR PERIOD ($MM)
FIRST QUARTER
2022 2021 Reported Operational (1) Currency
PULMONARY HYPERTENSION
US 572 573 -0.2% -0.2% -
Intl 279 288 -2.9% 4.0% -6.9%
WW 852 861 -1.1% 1.2% -2.3%
OPSUMIT
US 273 272 0.5% 0.5% -
Intl 170 179 -4.8% 2.0% -6.8%
WW 443 450 -1.6% 1.1% -2.7%
UPTRAVI
US 269 259 3.9% 3.9% -
Intl 56 46 20.9% 28.8% -7.9%
WW 325 305 6.5% 7.7% -1.2%
OTHER PULMONARY HYPERTENSION
US 30 42 -29.0% -29.0% -
Intl 53 63 -15.2% -8.4% -6.8%
WW 83 105 -20.8% -16.8% -4.0%
CARDIOVASCULAR / METABOLISM / OTHER (5)
US 672 799 -15.8% -15.8% -
Intl 238 245 -3.0% 0.9% -3.9%
WW 910 1,044 -12.8% -11.9% -0.9%
XARELTO
US 508 589 -13.8% -13.8% -
Intl - - - - -
WW 508 589 -13.8% -13.8% -
INVOKANA / INVOKAMET
US 60 87 -30.7% -30.7% -
Intl 68 63 7.5% 11.1% -3.6%
WW 128 150 -14.6% -13.1% -1.5%
OTHER
US 104 122 -14.9% -14.9% -
Intl 170 182 -6.6% -2.6% -4.0%
WW 274 305 -10.0% -7.5% -2.5%
TOTAL PHARMACEUTICAL
US 6,632 6,446 2.9% 2.9% -
Intl 6,237 5,655 10.3% 16.7% -6.4%
WW 12,869	$ 12,101 6.3% 9.3% -3.0%
See footnotes at end of schedule
% Change

-- 16 of 19 --

REPORTED SALES vs. PRIOR PERIOD ($MM)
FIRST QUARTER
MEDTECH SEGMENT (2,3,6) 2022 2021 Reported Operational (1) Currency
INTERVENTIONAL SOLUTIONS
US 494	$ 434 13.8% 13.8% -
Intl 597 514 16.2% 20.4% -4.2%
WW 1,092 949 15.1% 17.4% -2.3%
ORTHOPAEDICS
US 1,289 1,249 3.2% 3.2% -
Intl 899 864 4.1% 9.1% -5.0%
WW 2,188 2,113 3.5% 5.6% -2.1%
HIPS
US 225 209 7.3% 7.3% -
Intl 164 146 12.2% 17.0% -4.8%
WW 389 356 9.3% 11.3% -2.0%
KNEES
US 201 185 8.6% 8.6% -
Intl 138 132 4.1% 9.1% -5.0%
WW 339 317 6.7% 8.8% -2.1%
TRAUMA
US 475 450 5.5% 5.5% -
Intl 273 282 -3.3% 2.2% -5.5%
WW 748 733 2.1% 4.2% -2.1%
SPINE, SPORTS & OTHER
US 387 404 -4.1% -4.1% -
Intl 324 303 7.0% 11.7% -4.7%
WW 712 707 0.6% 2.7% -2.1%
% Change

-- 17 of 19 --

REPORTED SALES vs. PRIOR PERIOD ($MM)
FIRST QUARTER
2022 2021 Reported Operational (1) Currency
SURGERY
US 921 898 2.5% 2.5% -
Intl 1,513 1,474 2.7% 6.6% -3.9%
WW 2,434 2,372 2.6% 5.0% -2.4%
ADVANCED
US 417 405 3.0% 3.0% -
Intl 729 713 2.2% 5.4% -3.2%
WW 1,146 1,118 2.5% 4.5% -2.0%
GENERAL
US 504 493 2.1% 2.1% -
Intl 784 761 3.1% 7.7% -4.6%
WW 1,288 1,254 2.7% 5.5% -2.8%
VISION
US 521 472 10.4% 10.4% -
Intl 736 673 9.4% 16.4% -7.0%
WW 1,257 1,145 9.8% 13.9% -4.1%
CONTACT LENSES / OTHER
US 400 371 7.7% 7.7% -
Intl 511 486 5.1% 12.9% -7.8%
WW 910 857 6.2% 10.6% -4.4%
SURGICAL
US 121 101 20.2% 20.2% -
Intl 226 187 20.5% 25.7% -5.2%
WW 347 288 20.4% 23.8% -3.4%
TOTAL MEDTECH
US 3,225 3,054 5.6% 5.6% -
Intl 3,746 3,525 6.3% 11.1% -4.8%
WW 6,971	$ 6,579 5.9% 8.5% -2.6%
* Percentage greater than 100% or not meaningful
(1) Operational growth excludes the effect of translational currency
(2) Unaudited
(3) Certain prior year amounts have been reclassified to conform to current year product disclosures
(4) Reported as U.S. sales
(6) Previously referred to as Medical Devices
Note: Columns and rows within tables may not add due to rounding. Percentages have been calculated using actual, non-rounded figures and,
therefore, may not recalculate precisely.
(5) Refer to supplemental sales information schedule
% Change

-- 18 of 19 --

Full Year Q1 Q2 Q3 Q4 Full Year
CONSUMER HEALTH SEGMENT (1)
OTC (2)
US 2,460 599 675 686 633 2,594
Intl 2,761 673 752 798 811 3,034
WW 5,221 1,273 1,426 1,484 1,444 5,627
PHARMACEUTICAL SEGMENT (1)
INFECTIOUS DISEASES (2)
OTHER INFECTIOUS DISEASES
US 104 21 16 18 11 66
Intl 292 87 71 82 57 297
WW 396 108 88 99 68 363
NEUROSCIENCE (2)
OTHER NEUROSCIENCE
US 298 67 91 81 99 338
Intl 1,312 355 373 298 342 1,368
WW 1,610 422 464 379 441 1,706
CARDIOVASCULAR / METABOLISM / OTHER (2,3)
OTHER
US 600 122 116 98 110 446
Intl 794 182 178 173 140 673
WW 1,394 305 293 271 250 1,119
Note: Columns and rows within tables may not add due to rounding
(1) Unaudited
(3) Other is inclusive of PROCRIT / EPREX, which was previously disclosed separately
(2) Certain international OTC products, primarily in China, were reclassified from the Pharmaceutical segment to the Consumer Health segment
based on operational changes in their respective regions
Supplemental Sales Information
(Dollars in Millions)
Certain prior year amounts have been reclassified to
conform to current year product disclosures
2020 2021 2021

-- 19 of 19 --